SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB

[X]    QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934.

       For the quarterly period ended March 31, 2003.

       OR

[ ]    TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
       EXCHANGE ACT OF 1934.

       For the transition period from                    to
                                      ------------------    ------------------

       Commission file number

                          Ridgefield Acquisition Corp.
                          ----------------------------
       (Exact name of small business issuer as specified in its charter.)

        Colorado                       0-16335                   84-0922701
        --------                       -------                   ----------
(State or other jurisdiction      (Commission File             (IRS Employer
    of incorporation)                  Number)              Identification No.)


                 10 South Street, Ste. 202, Ridgefield, CT 06877

                                 (203) 894-9755
                                 --------------
                           (Issuer's telephone number,
                              including area code)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes   X    No
    -----     -----

As of May 12, 2003 the Registrant had outstanding 813,028 shares of common
stock, par value $.10

Transitional Small Business Disclosure Format (check one):
Yes        No   X
    -----     -----

<PAGE>

                          RIDGEFIELD ACQUISITION CORP.
                          (A Development Stage Company)
                                   FORM 10-QSB
                                 MARCH 31, 2003


                                                                            Page

PART I - FINANCIAL INFORMATION                                                3

Item 1.  Financial Statements                                                 3

         Consolidated Balance Sheets as of December 31, 2002 and
                  March 31, 2003 (unaudited)                                  3

         Consolidated Statements of Operations for the Three Months Ended
                  March 31, 2002 and 2003, Cumulative Amounts from
                  January 1, 2000 through March 31, 2003 (unaudited)          4

         Consolidated Statements of Cash Flows for the Three Months Ended
                  March 31, 2002 and 2003, Cumulative Amounts from
                  January 1, 2000 through March 31, 2003 (unaudited)          5

         Notes to Consolidated Financial Statements                           6


Item 2.  Management's Plan Of Operations                                      7

PART II - OTHER INFORMATION                                                  11

Item 5.  Other Information                                                   11

Item 6.  Exhibits & Reports on Form 8-K                                      11

SIGNATURES                                                                   12

                                        2
<PAGE>

                         PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements.


                          RIDGEFIELD ACQUISITION CORP.
                          (A Development Stage Company)
                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                     December 31,   March 31, 2003
                                                                         2002         (Unaudited)
<S>                                                                   <C>             <C>
                                                 ASSETS
CURRENT ASSETS
    Cash                                                              $   346,165     $   324,011
                                                                      -----------     -----------

        Total Current Assets                                              346,165         324,011
                                                                      -----------     -----------

                                                                      $   346,165     $   324,011
                                                                      ===========     ===========


                                     LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable and accrued expenses                             $    22,482     $    26,991
                                                                      -----------     -----------

        Total Current Liabilities                                          22,482          26,991
                                                                      -----------     -----------

STOCKHOLDERS' EQUITY
    Preferred Stock, $.10 par value; authorized - 1,000,000 shares
           Issued - none
    Common Stock, $.10 par value; authorized - 5,000,000 shares
           Issued and outstanding - 813,028 shares                         81,303          81,303
    Capital in excess of par value                                      1,595,509       1,595,509
    Accumulated (deficit)                                                (947,820)       (947,820)
    (Deficit) accumulated during the development stage                   (405,309)       (431,972)
                                                                      -----------     -----------

                                                                          323,683         297,020
                                                                      -----------     -----------

                                                                      $   346,165     $   324,011
                                                                      ===========     ===========
</TABLE>
          See accompanying notes to consolidated financial statements.

                                        3
<PAGE>

                          RIDGEFIELD ACQUISITION CORP.
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF OPERATIONS


                                                              Cumulative
                                      Three Months Ended      Amounts from
                                           March 31,        January 1, 2000
                                                                  to
                                      2002          2003     March 31, 2003

REVENUES
      Interest income              $   1,579     $   1,237     $  22,836
                                   ---------     ---------     ---------

OPERATING EXPENSES
    General and administrative        22,610        27,899       305,459
    Employee stock options           130,625
    Patent write-off                      --            --        18,724
                                   ---------     ---------     ---------
                                      22,610        27,899       454,808
                                   ---------     ---------     ---------


NET (LOSS)                         $ (21,031)    $ (26,662)    $(431,972)
                                   =========     =========     =========

NET (LOSS) PER COMMON SHARE        $   (0.03)    $   (0.03)    $    (.57)
                                   =========     =========     =========
    Basic and Diluted

WEIGHTED AVERAGE NUMBER OF
    COMMON SHARES OUTSTANDING -
    Basic and Diluted                813,023       813,028       762,752
                                   =========     =========     =========


          See accompanying notes to consolidated financial statements.

                                        4
<PAGE>

                          RIDGEFIELD ACQUISITION CORP.
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
                                                                                             Cumulative
                                                                      Three Months Ended    Amounts from
                                                                           March 31,       January 1, 2000
                                                                                                  to
                                                                       2002          2003   March 31, 2003
<S>                                                                <C>           <C>           <C>
CASH FLOWS FROM OPERATING ACTIVITES
        Net income (loss)                                          $ (21,031)    $ (26,662)    $(431,972)
        Adjustment to reconcile net income (loss) to net cash
            provided (used) by operating activities
            Stock issuance for salary                                 11,000            --        96,000
            Stock issued for professional services                        --            --        18,200
            Stock options compensation                                    --            --       130,625
            Write-off of patent                                           --            --        18,724
            Changes in assets and liabilities
            (Increase) decrease in note and interest receivable         (750)           --        50,000
            Increase (decrease) in accounts payable and
                    accrued expenses                                   4,610         4,508        11,597
                                                                   ---------     ---------     ---------

        Net Cash (Used) by Operating Activities                       (6,171)      (22,154)     (106,826)
                                                                   ---------     ---------     ---------

CASH FLOWS FROM INVESTING ACTIVITIES

        Net Cash (Used) in Investing Activities                           --            --            --
                                                                   ---------     ---------     ---------

CASH FLOWS FROM FINANCING ACTIVITIES
        Exercise of common stock warrants                                 --            --         5,625
                                                                   ---------     ---------     ---------

        Net Cash Provided by Financing Activities                         --            --         5,625
                                                                   ---------     ---------     ---------

NET (DECREASE) IN CASH                                                (6,171)      (22,154)     (101,201)

CASH, BEGINNING OF PERIODS                                           341,611       346,165       425,212
                                                                   ---------     ---------     ---------

CASH, END OF PERIODS                                               $ 335,440     $ 324,011     $ 324,011
                                                                   =========     =========     =========
</TABLE>
          See accompanying notes to consolidated financial statements.

                                        5
<PAGE>

         The unaudited financial statements included herein were prepared from
the records of the Company in accordance with Generally Accepted Accounting
Principles and reflect all adjustments which are, in the opinion of management,
necessary to provide a fair statement of the results of operations and financial
position for the interim periods. Such financial statements generally conform to
the presentation reflected in the Company's Form 10-KSB filed with the
Securities and Exchange Commission for the year ended December 31, 2002. The
current interim period reported herein should be read in conjunction with the
Company's Form 10-KSB subject to independent audit at the end of the year.

         The results of operations for the three months ended March 31, 2003 are
not necessarily indicative of the results that may be expected for the year
ending December 31, 2003.


NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION

On January 14, 2003, in connection with its reinstatement as an active
corporation in the State of Colorado, the Company changed its name from
Bio-Medical Automation, Inc. to Ridgefield Acquisition Corp.

On February 27, 2003, the Board of Directors of the Company authorized the
formation of a Nevada corporation named Bio-Medical Automation, Inc. and
authorized the management of the Company to transfer the Company's rights, title
and interest in its patent to Bio-Medical Automation, Inc. On March 3, 2003, the
Company filed Articles of Incorporation with the Secretary of State of the State
of Nevada to form Bio-Medical Automation, Inc., a Nevada corporation wholly
owned by the Company.

The accompanying financials statements as of March 31, 2003 and for the three
months then ended include the accounts of the company and its wholly owned
subsidiary. All intercompany accounts and transactions have been eliminated in
consolidation.

The Company has accumulated a deficit since reentering the development stage, on
January 1, 2000, of $431,972 through March 31, 2003. In 1999, the Company sold
all of its assets relating to its historical line of business and in 2000
abandoned its research and development efforts on a micro-robotic device. As of
March 31, 2003, the Company has no principal operations or revenue producing
activities. The Company is now pursuing an acquisition strategy whereby it is
seeking to arrange for a merger, acquisition or other business combination with
a viable operating entity.

NOTE 2 - RELATED PARTY TRANSACTIONS

On March 21, 2003, the Board of Directors renewed the President's employment
agreement through March 2004 with an annual salary of $48,000, and granted the
President an option to purchase 150,000 shares of the Company's common stock at
an exercise price of 110% of the closing market price as of the date of grant,
for a period of five years.

                                       6
<PAGE>

Item 2.  Management Discussion and Analysis and Plan of Operations

         The following discussion and analysis provides information which the
Company's management believes to be relevant to an assessment and understanding
of the Company's results of operations and financial condition. This discussion
should be read together with the Company's financial statements and the notes to
financial statements, which are included in this report, as well as the
Company's Annual Report on Form 10-KSB for the year ended December 31, 2002.

Background
-----------

        Ridgefield Acquisition Corp. ("RAC" or the "Company") was incorporated
as a Colorado corporation on October 13, 1983 under the name OZO Diversified
Automation, Inc. In March 1999, in connection with the sale of substantially all
of the Company's assets the Company changed its name to Bio-Medical Automation,
Inc. On April 1, 2002, the Company was administratively dissolved by the
Colorado Secretary of State for failing to timely file its bi-annual
registration with the Colorado Secretary of State. On January 14, 2003 the
Company filed an Application for Reinstatement pursuant to Section 7-114-203 of
the Colorado Revised Statutes. In connection with the reinstatement, and in
accordance with Colorado corporate law, the Company changed its name from
Bio-Medical Automation, Inc. to Ridgefield Acquisition Corp. The reinstatement
and name change became effective on January 14, 2003 when the Application for
Reinstatement was filed with the Colorado Secretary of State. Neither the
administrative dissolution nor reinstatement and name change has had or will
have any material effect on the holders of the securities of the Company.

        On March 9, 1999, the Company completed the sale of substantially all of
its assets to JOT Automation, Inc. (the "JOT Transaction"). As a result of the
JOT Transaction, the Company's historical business, the depaneling and routing
business, is considered to be a "discontinued operation" and, consequently,
provides no benefit to persons seeking to understand the Company's financial
condition or results of operations.

        Following the JOT Transaction the Company devoted its efforts to the
development of a prototype micro-robotic device (the "micro-robotic device") to
manipulate organic tissues on an extremely small scale. Due to the inability to
complete the micro-robotic device, the Company determined that it would cease
the development of the micro-robotic device and, as of June 30, 2000, the
capitalized costs related to the patent underlying the micro-robotic device have
been written off by the Company. The Company has never derived any revenues from
the micro-robotic device.

           Since July 2000 the Company has suspended all operations, except for
necessary administrative matters relating to the timely filing of periodic
reports as required by the Securities Exchange Act of 1934. Accordingly, during
the years ended December 31, 2002 and December 31, 2001, the Company has earned
no revenues from operations.

                                        7
<PAGE>

Acquisition Strategy
--------------------

           The Company's acquisition strategy is focused on seeking to arrange
for a merger, acquisition, business combination or other arrangement by and
between the Company and a viable operating entity. The Company has not
identified a viable operating entity for a merger, acquisition, business
combination or other arrangement, and there can be no assurance that the Company
will ever successfully arrange for a merger, acquisition, business combination
or other arrangement by and between the Company and a viable operating entity.

           The Company anticipates that the selection of a business opportunity
will be a complex process and will involve a number of risks, because
potentially available business opportunities may occur in many different
industries and may be in various stages of development. Due in part to depressed
economic conditions in a number of geographic areas, rapid technological
advances being made in some industries and shortages of available capital,
management believes that there are numerous firms seeking either the limited
additional capital which the Company will have or the benefits of a publicly
traded corporation, or both. The perceived benefits of a publicly traded
corporation may include facilitating or improving the terms upon which
additional equity financing may be sought, providing liquidity for principal
shareholders, creating a means for providing incentive stock options or similar
benefits to key employees, providing liquidity for all shareholders and other
factors.

     In some cases, management of the Company will have the authority to effect
acquisitions without submitting the proposal to the shareholders for their
consideration. In some instances, however, the proposed participation in a
business opportunity may be submitted to the shareholders for their
consideration, either voluntarily by the Board of Directors to seek the
shareholders' advice and consent, or because of a requirement of state law to do
so.

     In seeking to arrange a merger, acquisition, business combination or other
arrangement by and between the Company and a viable operating entity,
management's objective will be to obtain long-term capital appreciation for the
Company's shareholders. There can be no assurance that the Company will be able
to complete any merger, acquisition, business combination or other arrangement
by and between the Company and a viable operating entity.

     The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.

                                        8
<PAGE>

The Company Receives a U.S. Patent
----------------------------------

     Following the sale of substantially all of the Company's assets in 1999,
the Company devoted its efforts to the development of a prototype micro-robotic
device (the "micro-robotic device") to manipulate organic tissues on an
extremely small scale for microdissection. The Company filed a patent
application in February 1998, to protect certain features of the system and
method of the micro-robotic device. However, due to the inability of the Company
to complete the micro-robotic device, the Company determined that it would cease
development of the micro-robotic device and, as of June 30, 2000, the
capitalized costs related to the patent underlying the micro-robotic device have
been written off by the Company.

     On March 19, 2002, the Company was awarded United States Patent No. US
6,358,749 B1 for the "Automated System for Chromosome Microdissection and
Medthod of Using Same" (the "Patent").

           The Patent covers an automated system and method for microdissection
of samples such as chromosomes or other biological material, and in particular,
it relates to a robotic assisted microdissection system and method that
significantly reduces the time and skill needed for cellular and sub-cellular
dissections. Microdissection is defined as dissection under the microscope;
specifically: dissection of cells and tissues by means of fine needles that are
precisely manipulated by levers. The system and method covered by the Patent
attempts to provide reliability and ease of operation thereby making
microdissection widely available to laboratories. While the Company has never
derived any revenues from the micro-robotic device, the Company plans to attempt
to license or sell the technology covered by the Patent. There can be no
assurances that the Company will be able to successfully market the technology
covered by the Patent or that the Company will ever derive any revenues from the
Patent or the technology covered by the Patent.

           During the first quarter of 2003, the Board of Directors of the
Company authorized the formation of a wholly owned subsidiary of the Company for
the purposes of owning, developing and exploiting Patent. On March 3, 2003 the
Company filed Articles of Incorporation with the Secretary of State of the State
of Nevada to form Bio-Medical Automation, Inc., a Nevada corporation wholly
owned by the Company (the "Subsidiary"). A copy of the Articles of Incorporation
of Bio-Medical Automation, Inc. a Nevada corporation are attached as an Exhibit
to the Company's Current Report on Form 8-K filed on March 7, 2003 which is
incorporated herein by reference. The Board of Directors of the Company has
authorized management of the Company to transfer the Patent to the Subsidiary in
exchange for 5,000,000 shares of the common stock of the Subsidiary. The Company
plans to develop and exploit the Patent through the Subsidiary. There can be no
assurances that the Subsidiary will be able to successfully develop and/or
exploit the technology covered by the Patent.

                                        9
<PAGE>

Results of Operations
---------------------

         For the three months ended March 31, 2003, the Company has not earned
any revenues, except for interest income of $1,237. For the same period the
Company incurred general and administrative expenses of $27,899 resulting in a
net loss from operations equal to $26,662. General and administrative
expenditures were and have been directed to maintaining the Company's status as
a public company, including (without limitation) filing reports with the
Securities and Exchange Commission.

Liquidity and Capital Resources
-------------------------------

         During three months ended March 31, 2003, the Company satisfied its
working capital needs from cash on hand at the beginning of the quarter and cash
generated from interest income during the quarter. As of March 31, 2003, the
Company had on hand cash in the amount of $324,011.

        The Company's future financial condition will be subject to: (1) its
ability to arrange for a merger, acquisition or a business combination with an
operating business on favorable terms that will result in profitability, or (2)
its ability to successfully develop and exploit the Patent. There can be no
assurance that the Company will be able to do so or, if it is able to do so,
that the transaction will be on favorable terms not resulting in an unreasonable
amount of dilution to the Company's existing shareholders.

         The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.

         The Company may need additional funds in order to develop and
commercially exploit the Patent, although there is no assurance that the Company
will be able to obtain such additional funds, if needed. Even if the Company is
able to obtain additional funds there is no assurance that the Company will be
able to develop and commercially exploit the Patent.

         Except for historical information contained herein, the statements in
this report are forward-looking statements that are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. You
can identify these forward-looking statements when you see words such as
"expect," "anticipate," "estimate," "may," "believe," and other similar
expressions. These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Actual results could differ materially from those projected in the
forward-looking statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause the Company's actual results in future
periods to differ materially, from forecasted results. These and other risks are
described elsewhere herein and in the Company's other filings with the
Securities and Exchange Commission, namely the Company's Annual Report on Form
10-KSB for the year ended December 31, 2002.

                                       10
<PAGE>

                           PART II - OTHER INFORMATION


Item 5.  Other Information

     On March 24, 2001, the Company entered into an Employment Agreement with
Steven N. Bronson, the President of the Company. The terms of such Employment
Agreement include the following:

Name                       Title        Salary/Year        Term
-----------------------------------------------------------------
Steven N. Bronson     CEO & President     $48,000         1 year

     A copy of Mr. Bronson's Employment Agreement is attached as an Exhibit to
the Company's Form 10-QSB for the quarter ended March 31, 2001 and is
incorporated by reference. On March 21, 2003, the Board of Directors authorized
the renewal of Mr. Bronson's employment agreement with the Company for another
one (1) year term. Additionally, on March 21, 2003, the Company issued an option
to Steven N. Bronson to purchase 150,000 shares of the Company's common stock at
the purchase price of $1.65, which was 110% percent of the closing bid price on
March 21, 2003 and such option is exercisable for a period of 5 years.


Disclosure Controls and Procedures
----------------------------------

        Under the supervision and with the participation of our management,
including our principal executive officer, the Company has evaluated the
effectiveness of the design and operation of our disclosure controls and
procedures within 90 days of the filing date of this annual report, and, based
on their evaluation, our president has concluded that these controls and
procedures are effective. There were no significant changes in our internal
controls or in other factors that could significantly affect these controls
subsequent to the date of his evaluation.

        Disclosure controls and procedures are our controls and other procedures
that are designed to ensure that information required to be disclosed by us in
the reports that we file or submit under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the
Securities and Exchange Commission's rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by us in the reports that we
file under the Exchange Act is accumulated and communicated to our management,
including our principal executive and financial officer, as appropriate to allow
timely decisions regarding required disclosure.


Item 6.  Exhibits and Reports on Form 8-K

         a)  Exhibits

            99.1     President's Written Certification Of Financial Statements
                     Pursuant to 18 U.S.C. Statute 1350.


         b) On March 7, 2003, the Company filed a Current Report of Form 8-K
disclosing the Company's name change and the formation of a wholly owned
subsidiary Bio-Medical Automation, Inc., a Nevada corporation, which is
incorporated herein by reference.

                                       11
<PAGE>

                                   SIGNATURES


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.


Dated:  May 13, 2003


                                     RIDGEFIELD ACQUSITION CORP.


                                     By: /s/ Steven N. Bronson
                                         ------------------------------------
                                         Steven N. Bronson, President
                                         (Principle Executive Officer),
                                         as Registrant's duly authorized officer


                                       12
<PAGE>

       Statement Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
         By Principal Executive Officer and Principal Financial Officer
       Regarding Facts and Circumstances Relating to Exchange Act Filings


I, Steven N. Bronson, certify that:


1. I have reviewed this quarterly report on Form 10-QSB for the period ended
March 31, 2003;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and I have:

        a) designed such disclosure controls and procedures to ensure that
        material information relating to the registrant is made known to me by
        others, particularly during the period in which this quarterly report is
        being prepared;

        b) evaluated the effectiveness of the registrant's disclosure controls
        and procedures as of a date within 90 days prior to the filing date of
        this quarterly report (the "Evaluation Date"); and

        c) presented in this annual report my conclusions about the
        effectiveness of the disclosure controls and procedures based on my
        evaluation as of the Evaluation Date;

5. I have disclosed, based on my most recent evaluation, to the registrant's
auditors and the registrant's board of directors:

        a) all significant deficiencies in the design or operation of internal
        controls which could adversely affect the registrant's ability to
        record, process, summarize and report financial data and have identified
        for the registrant's auditors any material weaknesses in internal
        controls; and

        b) any fraud, whether or not material, that involves management or other
        employees who have a significant role in the registrant's internal
        controls; and

6. I have indicated in this quarterly report whether or not there were
significant changes in internal controls or in other factors that could
significantly affect internal controls subsequent to the date of my most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.

Date:  May 13, 2003.


                                            /s/ Steven N. Bronson
                                            ----------------------------------
                                            Steven N. Bronson, President

<PAGE>

                                  EXHIBIT INDEX

The following Exhibits are filed herewith:

Exhibit
Number      Description of Document
------      -----------------------
99.1        President's Written Certification Of Financial Statements
            Pursuant to 18 U.S.C. Statute 1350.